$UTMD

UTAH MEDICAL PRODUCTS INC

CIK:0000706698|SEC Filings

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME AND COMPREHENSIVE INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Details {2}
Sales, net	$ 8,529	$ 9,953	$ 17,252	$ 19,663
Cost of goods sold	3,771	4,358	7,212	8,530
Gross profit	4,758	5,595	10,040	11,133
Operating expense
Selling, general and administrative	1,955	2,264	4,517	4,495
Research & development	154	135	308	289
Total operating expenses	2,109	2,399	4,825	4,784
Operating income	2,649	3,196	5,215	6,349
Other income	637	640	1,254	1,345
Income before provision for income taxes	3,286	3,836	6,469	7,694
Provision for income taxes	600	788	1,179	1,605
Net income	$ 2,686	$ 3,048	$ 5,290	$ 6,089
Earnings per share, basic	$ 0.84	$ 0.94	$ 1.66	$ 1.86
Earnings per common share (diluted)	$ 0.84	$ 0.94	$ 1.66	$ 1.86
Shares outstanding - basic	3,184	3,246	3,184	3,278
Shares outstanding - diluted	3,184	3,246	3,184	3,278
Foreign currency translation net of taxes of $0 in all periods	$ (34)	$ 1,828	$ (536)	$ 2,546
Total comprehensive income	$ 2,652	$ 4,876	$ 4,754	$ 8,635

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOW - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income	$ 5,290	$ 6,089
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	421	405
Amortization	478	1,048
Provision for (recovery of) losses on accounts receivable	(12)	(7)
Amortization of Right-of-Use Assets	30	26
Deferred income taxes	(178)	(360)
Stock-based compensation expense	192	168
Tax benefit attributable to exercise of stock options	0	0
Accounts receivable and other receivables	(56)	409
Inventories	(1,130)	908
Prepaid expenses and other current assets	(22)	145
Accounts payable	(34)	37
Accrued expenses	(487)	(1,531)
Total adjustments	(798)	1,248
Net cash provided by operating activities	4,492	7,337
CASH FLOWS FROM INVESTING ACTIVITIES
Property and equipment	(264)	(235)
Net cash used in investing activities	(264)	(235)
CASH FLOWS FROM FINANCING ACTIVITIES
Common stock purchased and retired	(206)	(6,708)
Payment of dividends	(1,976)	(2,018)
Net cash used in financing activities	(2,182)	(8,726)
Effect of exchange rate changes on cash	(274)	827
Net increase/(decrease) in cash and cash equivalents	1,772	(797)
Cash at beginning of period	85,756	82,976
Cash at end of period	87,528	82,179
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION
Cash paid during the period for income taxes	1,660	2,327
Cash paid during the period for interest	$ 0	$ 0

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets
Cash & Investments	$ 87,528	$ 85,756
Accounts & other receivables, net	3,565	3,522
Inventories	9,003	7,935
Other current assets	543	529
Total current assets	100,639	97,742
Property and equipment, net	9,631	9,908
Goodwill	13,956	14,052
Other intangible assets	55,459	55,941
Other intangible assets - accumulated amortization	(55,113)	(55,101)
Other intangible assets, net	346	840
Total assets	124,572	122,542
Current liabilities
Accounts payable	876	911
Accrued expenses	1,194	1,687
Total current liabilities	2,070	2,598
Deferred tax liability - Femcare IIA	0	114
Long-term lease liability	195	225
Deferred income taxes	274	337
Total liabilities	2,539	3,274
Stockholders' equity
Common stock - $.01 par value; authorized - 50,000 shares; issued and outstanding - June 30, 2026, 3,183 shares and December 31, 2025, 3,186 shares	32	32
Accumulated other comprehensive loss	(9,953)	(9,416)
Additional paid-in capital	0	0
Retained earnings	131,954	128,652
Total stockholders' equity	122,033	119,268
Total liabilities and stockholders' equity	$ 124,572	$ 122,542